Senhwa Biosciences, Inc. (TPEX:6492)
Taiwan · Delayed Price · Currency is TWD 29.70
-0.15 (-0.50%)
Nov 13, 2026, 1:24 PM CST
Senhwa Biosciences Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.96 | 1.07 | 1 | 1 | 1 | 0.55 | |
Revenue Growth | -11.11% | 7.00% | 0% | 0% | 81.82% | -10.86% |
Cost of Revenue | 0.52 | 0.55 | 0.52 | 0.45 | 0.5 | 0.23 |
Gross Profit | 0.45 | 0.52 | 0.48 | 0.55 | 0.51 | 0.32 |
Selling, General & Admin | 70.9 | 61.03 | 62.93 | 54.79 | 43.77 | 71.17 |
Research & Development | 253.43 | 217.75 | 243.74 | 256.87 | 312.85 | 275.47 |
Operating Expenses | 324.33 | 278.78 | 306.67 | 311.66 | 356.62 | 346.64 |
Operating Income | -323.88 | -278.26 | -306.19 | -311.11 | -356.12 | -346.32 |
Interest Expense | -0.72 | -0.75 | -0.66 | -0.54 | -0.54 | -0.53 |
Interest & Investment Income | 7.03 | 7.25 | 6.11 | 7.64 | 7.32 | 4.61 |
Currency Exchange Gain (Loss) | 1.2 | 1.2 | -1.19 | 0.49 | -1 | 1.24 |
Other Non Operating Income (Expenses) | -3.88 | 0.96 | 0.8 | - | 0.01 | 0.92 |
EBT Excluding Unusual Items | -320.24 | -269.61 | -301.14 | -303.52 | -350.34 | -340.06 |
Gain (Loss) on Sale of Investments | 6.16 | 6.16 | 8.68 | 8.04 | 2.08 | 1.52 |
Other Unusual Items | 0.01 | 0.01 | - | 0.43 | - | 10.2 |
Pretax Income | -314.07 | -263.44 | -292.46 | -295.05 | -348.26 | -328.35 |
Income Tax Expense | 1.34 | 1.33 | 1.28 | 1.26 | 1.37 | 0.91 |
Net Income | -315.41 | -264.77 | -293.75 | -296.31 | -349.63 | -329.26 |
Net Income to Common | -315.41 | -264.77 | -293.75 | -296.31 | -349.63 | -329.26 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 92 | 89 | 89 | 89 | 89 | 90 |
Shares Outstanding (Diluted) | 92 | 89 | 89 | 89 | 89 | 90 |
Shares Change | 3.23% | 0.03% | - | -0.00% | -0.50% | 13.49% |
EPS (Basic) | -3.43 | -2.97 | -3.29 | -3.32 | -3.92 | -3.67 |
EPS (Diluted) | -3.43 | -2.97 | -3.29 | -3.32 | -3.92 | -3.67 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -263.55 | -248.74 | -296.17 | -299 | -400.34 | -300.29 |
Free Cash Flow Per Share | -2.86 | -2.79 | -3.32 | -3.35 | -4.49 | -3.35 |
Gross Margin | 46.35% | 48.60% | 47.70% | 55.20% | 50.50% | 58.73% |
Operating Margin | -33737.71% | -26005.51% | -30619.10% | -31111.10% | -35611.50% | -62966.54% |
Profit Margin | -32855.10% | -24744.77% | -29374.50% | -29630.60% | -34963.20% | -59864.91% |
Free Cash Flow Margin | -27453.44% | -23246.45% | -29617.30% | -29900.10% | -40034.00% | -54597.64% |
EBITDA | -322.31 | -276.08 | -303.94 | -309.53 | -355.81 | -345.86 |
D&A For EBITDA | 1.57 | 2.18 | 2.25 | 1.58 | 0.31 | 0.46 |
EBIT | -323.88 | -278.26 | -306.19 | -311.11 | -356.12 | -346.32 |